Cord Blood America’s CEO, Matthew Schissler, was featured in an exlusive interview with Jason Buchen at EquityGroups. The entire interview can be heard at this link: Cord Blood America Interview
In the interview, the CEO said that investors should be increasingly interested in the stem cell sector because many more diseases will be treated and cured by stem cells. Stem cells are remarkable for their ability to develop into many different cell types, allowing them to repair damaged areas and cure diseases that were previously considered incurable.
He also said, “We are the fastest growing stem cell company that we know about, and are highly undervalued. We are positioning our Company to be in control of the inventory, which is crucial to significant corporate growth.”
Let us hear your thoughts: Cord Blood America Inc. Message Board
